Randomized trial shows lumateperone improves depression symptoms in patients, indicating efficacy in adjunctive therapy.
Patients receiving lumateperone 42 mg plus ADT had statistically significant and clinically meaningful improvement in depression symptoms and disease severity compared with those receiving placebo+ADT. Lumateperone+ADT was generally safe and well tolerated in patients with MDD with inadequate ADT response.
No takes yet. Share an insight, caveat, or question.
Edwards et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: